Hims, weight loss

Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 market — which is projected to hit $105 billion by 2030, according to Morgan Stanley (MS) analysts.
Hims & Hers Stock Is Due for a Crash Diet. The Weight-Loss Drug Surge Is Fading Fast.
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm that began selling the drugs last spring.
Analysts Have Mixed Reviews on Hims & Hers Stock Amid Uncertainty Around Weight Loss Business
Telehealth company Hims & Hers Health (HIMS) witnessed a major dip in its stock recently despite reporting 95% revenue growth for the
Hims & Hers' Weight-Loss Bet Hits a Wall--Is the Stock's $6 Billion Surge About to Unravel?
With the FDA shutting down its key revenue stream, Hims faces a tough road ahead--can it justify its valuation?
Hims and Hers just shut down its dermatology business after stock slump on FDA's weight-loss drug decision
Hims and Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public telehealth company.
Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment.
Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo stock slides 4%
Roche is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma , the companies announced Wednesday. The deal would
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.
Roche-Zealand deal is the latest to boost obesity space
Viking Therapeutics (VKTX) stock gains as Roche (RHHBY) and Zealand Pharma's (ZLDPF) $5.3B deal for obesity drugs lifts weight loss drug stocks. Read more here.
The FDA Cracking Down on Compounded Weight Loss Drugs – Here’s What It Means for Telehealth Companies and Consumers
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
‘Don’t Buy the Dip,’ Says Morgan Stanley About Hims & Hers Stock
Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...
Why Hims & Hers Health Stock Just Popped
Roller-coaster healthcare stock Hims & Hers Health ( HIMS -1.34%), whose stock got devastated last week by worries that it ...
This Could Be a Huge Blow to Hims & Hers Health Stock
Hims & Hers Health (NYSE: HIMS) has been a top healthcare stock to own over the past five years, soaring by around 350% ...
Hims & Hers: AI-Powered Healthcare Disruption
Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...